Across 6 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Edwards Lifesciences news is Bullish (+64)
on a scale from −100 to +100.
That is up 15 points from the previous 30 days (+49).
📉 VP Donald Bobo, Jr. sold 48,900 shares for $5.04 million under a pre-arranged Rule 10b5-1 trading plan on November 9th.
💰 The company reported Q3 EPS of $0.80, beating the consensus estimate of $0.74 by $0.06.
📈 Revenue reached $1.72 billion, surpassing the $1.68 billion consensus and growing 10.5% year-over-year.
🏦 Institutional ownership stands at 79.46%, with Intech Investment Management increasing its stake by 123.9% in Q3.
🎯 Analysts maintain a 'Moderate Buy' consensus with an average price target of $108.88, up from recent lows.
📊 The stock trades at a P/E ratio of 59.16 and has a market capitalization of $60.29 billion.
📈 Bullish signals
💰Edwards Lifesciences beat Q3 earnings estimates with $0.80 EPS versus the consensus of $0.74.
📈Revenue grew 10.5% year-over-year to $1.72 billion, exceeding analyst expectations of $1.68 billion.
🎯Goldman Sachs raised its price target to $102.00 and reaffirmed a 'buy' rating on the stock.
🏦Intech Investment Management increased its stake by 123.9% in Q3, now holding shares valued at $16.6 million.
🎯Truist Financial set a price objective of $113.00 with a 'buy' rating following the earnings beat.
🎯Piper Sandler raised its price target to $115.00 and maintained an 'overweight' rating on the company.
📉 Risk factors
📉VP Donald Bobo, Jr. reduced his personal shareholding by 68.2% following a $5.04 million sale.
📊The stock trades at a high P/E ratio of 59.16, which may limit upside potential if growth slows.
Article
Edwards Lifesciences Corporation (NYSE:EW) saw Vice President Donald Bobo, Jr. sell 48,900 shares on November 9th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $103.05 per share, totaling approximately $5.04 million, reducing his personal holding to roughly 22,798 shares. This insider sale represents a significant decrease in his position but was executed via a standard compliance plan.
The company reported strong quarterly financial results on November 4th, beating analyst expectations for both earnings per share and revenue. Edwards Lifesciences posted $0.80 EPS compared to the consensus of $0.74, while revenue reached $1.72 billion against an estimate of $1.68 billion. Year-over-year revenue growth stood at 10.5%, driven by its structural heart disease therapies and critical care technologies.
Market sentiment remains robust with a consensus price target of $108.88, supported by recent upgrades from major analysts including Goldman Sachs, Jefferies, and Truist Financial. Institutional ownership is high at 79.46%, with several funds like Intech Investment Management increasing their stakes in the third quarter. The stock trades at a P/E ratio of 59.16 with a market capitalization of $60.29 billion.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Truist Financial has raised its price target for Edwards Lifesciences (NYSE:EW) from $90.00 to $95.00, citing potential upside of 10.82% from current levels, though maintaining a 'hold' rating. This move aligns with broader analyst sentiment, as the consensus rating remains 'Moderate Buy' with an average target price of $98.95. Other major institutions like Royal Bank of Canada and Mizuho have also recently increased their targets to $110.00 and $105.00 respectively, while TD Cowen upgraded its rating to 'buy' with a $104.00 target.
Edwards Lifesciences reported strong financial results for the quarter ended April 23rd, posting earnings per share of $0.78 against consensus estimates of $0.73. Revenue reached $1.65 billion, representing a 16.7% year-over-year increase compared to analyst expectations of $1.60 billion. The company demonstrated robust profitability with a net margin of 17.39% and a return on equity of 15.19%. Management has provided forward guidance for fiscal year 2026 EPS between $2.95 and $3.05, exceeding the average analyst expectation of $3.00.
Despite positive financials and analyst upgrades, insider activity shows some executives reducing their stakes. VP Donald E. Bobo, Jr. sold over 2 million dollars worth of shares, while SVP Andrew M. Dahl also reduced his position slightly. However, institutional ownership remains high at 79.46%, with significant increases in holdings from major funds like Handelsbanken Fonder AB and Investors Research Corp during the second quarter, indicating continued confidence in the company's long-term prospects.
📈 Truist raised Edwards Lifesciences price target to $95.00.
🏆 Q2 earnings beat estimates at $0.78 per share.
💰 Revenue surged 16.7% year-over-year to $1.65 billion.
🔮 FY 2026 EPS guidance set between $2.95 and $3.05.
📉 VP Bobo sold over $2 million in shares.
📈 Truist Financial raised its price target for Edwards Lifesciences to $95.00 from $90.00, projecting a 10.82% upside.
🏆 The company reported Q2 earnings of $0.78 per share, beating analyst estimates by $0.05.
💰 Revenue surged to $1.65 billion, marking a 16.7% increase year-over-year.
📊 Net margins stood strong at 17.39% with a return on equity of 15.19%.
🔮 Management guided for FY 2026 EPS between $2.95 and $3.05, above analyst consensus.
📉 VP Donald E. Bobo, Jr. sold 23,145 shares worth over $2 million in a single transaction.
📈 Royal Bank of Canada increased its target price to $110.00 with an 'outperform' rating.
📈 TD Cowen restated its rating to 'buy' and raised the target price to $104.00.
🏦 Institutional ownership remains robust at 79.46% of total shares outstanding.
📉 Handelsbanken Fonder AB significantly boosted its position by 22.0% in Q2.
❤️ The company specializes in structural heart disease therapies and transcatheter aortic valve replacement (TAVR).
📰 MarketBeat reports the consensus rating is 'Moderate Buy' with an average target of $98.95.
Bullish Signals
Analysts see 10.82% upside to Truist's $95.00 price target.
Company beat EPS estimates, reporting $0.78 versus $0.73 consensus.
Revenue grew 16.7% YoY to $1.65 billion, beating expectations.
Consensus rating is Moderate Buy with average target of $98.95.
Major banks raised targets to $110.00 and $105.00.
Risk Factors
VP Bobo sold 23,145 shares ($2M), dropping ownership 19.01%.
SVP Dahl sold 568 shares ($49K) to reduce holdings.
Bullish Signals
Truist Financial increased its price target to $95.00, indicating a 10.82% potential upside from current levels.
The company beat quarterly earnings estimates by $0.05 per share, reporting $0.78 EPS versus the consensus of $0.73.
Revenue grew 16.7% year-over-year to reach $1.65 billion, surpassing analyst expectations of $1.60 billion.
Analyst sentiment is broadly positive with a 'Moderate Buy' consensus rating and an average target price of $98.95.
Major institutions like Royal Bank of Canada and Mizuho have raised their price targets to $110.00 and $105.00 respectively.
TD Cowen upgraded its rating to 'buy' with a new target price of $104.00, up from $97.00.
Management provided forward guidance for FY 2026 EPS between $2.95 and $3.05, which exceeds the average analyst forecast of $3.00.
Institutional investors are accumulating shares, with Handelsbanken Fonder AB increasing its stake by 22.0% in Q2.
Risk Factors
VP Donald E. Bobo, Jr. sold 23,145 shares worth approximately $2 million, reducing his ownership by 19.01%.
SVP Andrew M. Dahl also reduced his holdings by selling 568 shares worth roughly $49,000.
Edwards Lifesciences Corp. has agreed to pay a $10 million penalty related to its 2024 acquisition of JC Medical, which was formerly a subsidiary of Genesis MedTech. The Federal Trade Commission alleges that both Edwards and Genesis intentionally structured the transaction to avoid federal premerger filing requirements under antitrust laws.
Under the terms of the final judgment, Genesis will also be required to pay a $2 million penalty. This regulatory action stems from the FTC's complaint regarding the avoidance of necessary review processes for the deal involving the Singapore-based company and Edwards.
📉 Edwards Lifesciences shares dropped 2% to $90.03 after penalty news.
💰 Company agreed to pay $10 million in JC Medical acquisition penalties.
⚖️ FTC alleges intentional deal structuring to bypass federal premerger filings.
🏢 JC Medical was formerly a subsidiary of Singapore-based Genesis MedTech.
📝 Genesis will pay separate $2 million penalty under final judgment terms.
📉 Edwards Lifesciences shares dropped 2% to $90.03 following the announcement of the penalty.
💰 The company agreed to pay a total of $10 million in penalties linked to the JC Medical acquisition.
⚖️ The FTC alleges that Edwards and Genesis intentionally structured the deal to bypass federal premerger filing requirements.
🏢 JC Medical was formerly a subsidiary of Singapore-based Genesis MedTech before the acquisition.
📝 Genesis will also pay a separate $2 million penalty as part of the final judgment terms.
Risk Factors
Company faces $10M antitrust penalty for JC Medical acquisition.
Stock price dropped 2% to $90.03 after settlement news.
Genesis MedTech liable for additional $2M penalty.
Risk Factors
Edwards Lifesciences faces a $10 million financial penalty for allegedly avoiding required antitrust review on its JC Medical acquisition.
The company's stock price declined by 2% to $90.03 immediately following the news of the regulatory settlement.
Genesis MedTech will also be liable for a $2 million penalty under the final judgment terms regarding the deal structure.
24/7 Wall St. has issued a price target of $111.36 for Edwards Lifesciences Corp (EW) over the next 12 months, implying a 17.45% upside from the current trading price of $94.82. The analysis categorizes the stock as attractively valued with a favorable risk-reward profile for investors holding a one-year horizon.
Wall Street consensus remains bullish, with 21 out of 29 analysts rating EW as a Buy and 8 as Hold, resulting in a 72% buy rating. The proprietary model projects an optimistic scenario where the stock could reach $127.71, representing a 34.7% gain, assuming strong earnings growth and successful execution of company initiatives.
Conversely, the conservative scenario places the price floor at $97.47, suggesting limited downside risk as the stock trades roughly flat or slightly higher than current levels even under adverse conditions. Long-term projections through 2030 estimate an average price of $142.24, contingent on company execution and broader market dynamics.
The article concludes with standard disclaimers noting that these forecasts are forward-looking estimates incorporating analyst consensus and valuation metrics rather than guarantees. Actual performance may vary due to earnings surprises, macroeconomic changes, and market psychology.
🎯 24/7 Wall St. targets $111.36 for Edwards Lifesciences (EW).
📊 Analysts show strong sentiment with 21 Buy vs 8 Hold ratings.
🚀 Optimistic scenario projects EW reaching $127.71 within a year.
🛡️ Conservative floor at $97.47 limits downside risk significantly.
📈 Long-term average price through 2030 forecasted at $142.24.
🎯 24/7 Wall St. sets a 12-month price target of $111.36 for Edwards Lifesciences Corp (EW), implying a 17.45% upside from the current price of $94.82.
📊 Wall Street sentiment is predominantly positive with 21 Buy ratings and 8 Hold ratings among 29 analysts covering the stock.
🚀 The optimistic scenario projects EW reaching $127.71 over the next year, representing a potential 34.7% gain from current levels.
🛡️ The conservative scenario establishes a price floor at $97.47, indicating limited downside risk and a roughly flat outlook for the stock.
📈 Long-term forecasts through 2030 project an average trading price of $142.24 with a potential range between $106.68 and $177.80.
💡 The analysis incorporates analyst consensus, valuation metrics, technical indicators, and market sentiment into its proprietary pricing model.
Bullish Signals
Rated BUY with 17.4% upside potential.
72% analyst buy consensus rating.
Conservative scenario limits downside risk.
Potential 50.0% return by 2030.
Bullish Signals
The stock is rated as a BUY by 24/7 Wall St. with a strong upside potential of 17.4% to the target price.
Wall Street analyst consensus shows a 72% buy rating, indicating broad institutional confidence in the company's prospects.
The conservative scenario suggests limited downside risk, projecting the stock to remain flat or slightly higher than current levels.
Long-term projections indicate a potential 50.0% return from today's price by 2030 if execution and market conditions align favorably.
Edwards Lifesciences (NYSE:EW) received a rating downgrade to 'Hold' from Wall Street Zen, contrasting with mixed signals from other major firms like TD Cowen and Barclays which maintained buy ratings or raised price targets. The consensus average rating remains 'Moderate Buy' with a target price of $96.39, though recent analyst actions reflect divergent views on the stock's immediate trajectory.
The company reported strong financial results for the quarter ended April 23rd, beating earnings estimates with $0.78 EPS and revenue of $1.65 billion, a 16.7% year-over-year increase. Management provided forward guidance for FY 2026 EPS between $2.95 and $3.05, indicating continued growth expectations despite the mixed analyst sentiment.
Insider trading activity shows net selling by senior executives, including SVP Andrew Dahl and VP Daniel Lippis, who reduced their holdings under pre-arranged plans over the last ninety days. While institutional ownership remains high at 79.46%, these insider sales suggest caution among company leadership regarding current valuation levels.
📉 Wall Street Zen downgraded stock to 'Hold'.
📈 Analysts raised price targets to $104-$110.
💰 Q2 EPS beat estimates at $0.78.
📊 Revenue surged 16.7% to $1.65 billion.
🔮 FY 2026 EPS guidance set between $2.95-$3.05.
📉 Wall Street Zen downgraded Edwards Lifesciences from 'Buy' to 'Hold', adding to a mixed analyst landscape.
📈 TD Cowen reiterated a 'Buy' rating and raised the price target to $104.00, while Barclays set a target of $110.00.
💰 The company reported Q2 EPS of $0.78, surpassing the consensus estimate of $0.73.
📊 Revenue reached $1.65 billion, representing a 16.7% increase compared to the prior year period.
🔮 Management guided for FY 2026 EPS between $2.95 and $3.05.
👤 SVP Andrew Dahl sold 568 shares worth approximately $48,893 in a pre-arranged transaction.
👤 VP Daniel Lippis sold 619 shares worth approximately $56,576 under a Rule 10b5-1 plan.
📉 Insiders have collectively sold 58,977 shares valued at over $4.9 million in the last ninety days.
🏦 Institutional investors maintain a dominant stake, owning 79.46% of the company's float.
🔬 Edwards focuses on structural heart disease therapies, including transcatheter aortic valve replacement (TAVR) technologies.
Bullish Signals
Beat EPS expectations at $0.78 vs $0.73 consensus.
Revenue surged 16.7% YoY to $1.65 billion.
FY 2026 guidance projects EPS between $2.95 and $3.05.
TD Cowen raised target to $104 with Buy rating.
Barclays set higher target of $110 with Overweight rating.
Risk Factors
Wall Street Zen downgraded stock from Buy to Hold.
Executives sold over $4.9 million in shares recently.
Average analyst price target of $96.39 is low.
Bullish Signals
Edwards Lifesciences beat quarterly earnings expectations with $0.78 EPS versus the consensus of $0.73.
Revenue grew significantly by 16.7% year-over-year to reach $1.65 billion.
The company provided robust full-year guidance for FY 2026, projecting EPS between $2.95 and $3.05.
TD Cowen raised its price target to $104.00 and maintained a 'Buy' rating on the stock.
Barclays reiterated an 'Overweight' rating with a higher price target of $110.00.
Risk Factors
Wall Street Zen downgraded the stock from 'Buy' to 'Hold', signaling caution among some analysts.
Senior executives, including SVP Andrew Dahl and VP Daniel Lippis, sold shares totaling over $4.9 million in the last ninety days.
The average analyst price target of $96.39 is below the recent highs set by individual firms like Barclays.
ABN AMRO Bank N.V. significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 124.5% in the first quarter, purchasing an additional 220,969 shares. This brings ABN AMRO's total holding to 398,425 shares, valued at approximately $32.26 million as of their latest SEC filing. Other major institutional investors also expanded their positions during the fourth quarter, including State Street Corp, Wellington Management Group LLP, Norges Bank, Morgan Stanley, and Marshall Wace LLP, collectively signaling strong institutional confidence in the medical technology company.
Edwards Lifesciences reported robust financial performance for the quarter ended April 23rd, beating analyst expectations on both earnings per share and revenue. The company posted $0.78 EPS compared to a consensus of $0.73, with revenue reaching $1.65 billion against an estimate of $1.60 billion. Year-over-year revenue growth was 16.7%, driven by strong demand for its structural heart disease products and critical care monitoring solutions. The company maintains healthy margins with a net margin of 17.39% and a return on equity of 15.19%.
Analyst sentiment remains positive following the earnings beat, with several major firms raising price targets or restating buy ratings. TD Cowen raised its price target to $104.00, while Barclays increased its target to $110.00 and Evercore set a target of $93.00. The consensus analyst price target stands at $95.96 with a 'Moderate Buy' rating. Despite some insider selling by executives VP Daniel J. Lippis and CFO Scott B. Ullem under pre-arranged trading plans, the overall institutional accumulation suggests a bullish outlook for the stock.
📈 ABN AMRO increased EW holdings by 124.5% to $32.26 million in Q1.
🏦 State Street Corp holds 25.99 million shares valued at $2.22 billion.
💰 Q1 EPS of $0.78 beat estimates; revenue grew 16.7% YoY to $1.65B.
🎯 TD Cowen raised price target to $104.00 with a 'buy' rating.
🔮 FY 2026 EPS guidance ranges between $2.95 and $3.05.
📈 ABN AMRO Bank N.V. increased its EW holdings by 124.5% in Q1, adding 220,969 shares to reach a total value of $32.26 million.
🏦 State Street Corp grew its position by 1.5%, now holding 25.99 million shares valued at $2.22 billion.
📊 Wellington Management Group LLP raised its stake by 4.8% to own 21.79 million shares worth $1.86 billion.
🇳🇴 Norges Bank initiated a new stake in EW valued at $803.69 million during the fourth quarter.
📈 Morgan Stanley lifted its position by 12.4%, acquiring an additional 804,942 shares for $623.54 million.
🚀 Marshall Wace LLP significantly increased holdings by 66.1%, purchasing 2.36 million shares worth $505.16 million.
💰 Edwards Lifesciences reported Q1 EPS of $0.78, beating the consensus estimate of $0.73 by $0.05.
📈 Revenue reached $1.65 billion for the quarter, surpassing the $1.60 billion consensus and growing 16.7% year-over-year.
💹 The company achieved a net margin of 17.39% and a return on equity of 15.19% during the reporting period.
🎯 TD Cowen restated a 'buy' rating with an increased price target of $104.00, up from $97.00.
📉 VP Daniel J. Lippis sold 620 shares for $50,306.80 under a Rule 10b5-1 trading plan on May 18th.
💸 CFO Scott B. Ullem sold 13,000 shares for $1,040,520.00 on April 9th under a pre-arranged trading plan.
📉 Over the last ninety days, insiders sold a total of 81,038 shares valued at $6.68 million.
🏥 The company focuses on structural heart disease therapies, including the SAPIEN family of transcatheter heart valves.
🔮 Edwards Lifesciences provided FY 2026 EPS guidance ranging between $2.95 and $3.05.
Bullish Signals
ABN AMRO increased holdings by 124.5% to 398,425 shares valued at $32.26 million.
State State Corp owns 25,991,524 shares worth $2.22 billion after a 1.5% increase.
Edwards Lifesciences Q1 EPS of $0.78 beat the consensus estimate of $0.73.
Revenue reached $1.65 billion, growing 16.7% year-over-year and exceeding estimates.
Net margin is 17.39% with a return on equity of 15.19%.
Risk Factors
Insiders sold 81,038 shares worth $6.68 million in 90 days.
VP Lippis sold 620 shares for $50,306.80 on May 18th.
CFO Ullem sold 13,000 shares for $1.04M on April 9th.
Bullish Signals
ABN AMRO Bank N.V. increased its holdings in Edwards Lifesciences by 124.5% in the first quarter, adding 220,969 shares to a total holding of 398,425 shares valued at $32.26 million.
State Street Corp grew its position by 1.5% in the fourth quarter, now owning 25,991,524 shares worth $2.22 billion.
Wellington Management Group LLP raised its holdings by 4.8%, acquiring an additional 989,533 shares to reach a total value of $1.86 billion.
Norges Bank initiated a new stake in the company valued at $803.69 million during the fourth quarter.
Morgan Stanley lifted its position by 12.4%, purchasing an additional 804,942 shares worth $623.54 million.
Marshall Wace LLP grew its holdings by 66.1% in the fourth quarter, adding 2,359,128 shares valued at $505.16 million.
Edwards Lifesciences reported Q1 EPS of $0.78, beating the consensus estimate of $0.73 by $0.05.
Revenue for the quarter reached $1.65 billion, exceeding the consensus estimate of $1.60 billion and growing 16.7% year-over-year.
The company achieved a net margin of 17.39% and a return on equity of 15.19%, demonstrating strong profitability.
TD Cowen restated a 'buy' rating and raised its price target to $104.00 from $97.00 following the earnings beat.
Barclays restated an 'overweight' rating and increased its price target to $110.00 from $104.00.
Evercore reissued an 'outperform' rating with a price target of $93.00, indicating continued analyst confidence.
Mizuho set a price target of $95.00 and maintained an 'outperform' rating on the stock.
The consensus analyst price target is $95.96 with a 'Moderate Buy' rating based on 27 total analysts covering the stock.
Risk Factors
Company insiders sold a total of 81,038 shares valued at $6.68 million over the last ninety days.
VP Daniel J. Lippis sold 620 shares for $50,306.80 on May 18th, reducing his personal ownership by 1.51%.
CFO Scott B. Ullem sold 13,000 shares for $1,040,520.00 on April 9th, representing a 24.67% decrease in his position.
Simply Wall St's valuation analysis of Edwards Lifesciences (EW) indicates the stock is fairly valued based on a Discounted Cash Flow (DCF) model but appears overvalued relative to its P/E multiple. The DCF model, utilizing a two-stage free cash flow to equity approach with projections extending to 2035, estimates an intrinsic value of $91.82 per share against the recent trading price of $89.72.
The analysis highlights a significant discrepancy in valuation metrics when comparing earnings multiples. Edwards Lifesciences currently trades at a P/E ratio of 48.03x, which is substantially higher than its calculated Fair Ratio of 29.06x and the industry average of approximately 25x. While the DCF suggests a minimal 2.3% undervaluation, the high multiple relative to peers and the proprietary fair value metric presents a conflicting signal regarding the stock's current pricing.
The article notes that the company provides cardiovascular disease treatments in major markets including the US, Europe, and Japan. It concludes by suggesting that investors can utilize the platform's narrative tools to adjust assumptions for revenue and earnings to form their own buy or sell frameworks, as the provided analysis relies on historical data and analyst forecasts rather than real-time price-sensitive announcements.
📊 DCF Model values shares at $91.82, implying 2.3% undervaluation.
💰 Stock trades at $89.72 with projected 2028 free cash flow of $1.93b.
📈 High P/E ratio of 48.03x exceeds fair value of 29.06x.
🏥 Company operates globally treating advanced cardiovascular diseases in US, Europe, and Japan.
📉 Valuation check score is 1/6 due to high P/E multiples.
📊 DCF Model Valuation: The intrinsic value is estimated at $91.82 per share based on projected free cash flows extending to 2035.
💰 Current Price vs Intrinsic Value: The stock trades at $89.72, implying a small 2.3% undervaluation according to the DCF model.
📈 P/E Ratio Analysis: Edwards Lifesciences trades at a high multiple of 48.03x compared to a calculated Fair Ratio of 29.06x and an industry average of 24.97x.
🏥 Market Presence: The company provides technologies for treating advanced cardiovascular diseases in the US, Europe, Japan, and internationally.
📉 Valuation Check Score: The platform assigns a score of 1/6 on its valuation checks, citing high P/E multiples as a red flag.
🔮 Projection Data: Analyst estimates feed into the forecast with projected free cash flow reaching $1.93b for the year 2028.
🛠️ Investor Tools: The article promotes the platform's ability to create custom investment narratives using user-defined assumptions for revenue and margins.
Bullish Signals
DCF model shows 2.3% undervaluation vs $91.82 intrinsic value.
Global operations provide cardiovascular treatments in US, Europe, Japan.
Risk Factors
P/E ratio of 48.03x is double fair value of 29.06x.
Valuation score of 1/6 flags high P/E multiples as a risk.
Bullish Signals
The DCF model indicates the stock is technically undervalued by 2.3% relative to its estimated intrinsic value of $91.82.
The company operates in a global market providing advanced cardiovascular disease treatments across major regions including the US, Europe, and Japan.
Risk Factors
The stock trades at a P/E ratio of 48.03x, which is nearly double the calculated Fair Ratio of 29.06x and significantly higher than the industry average.
Simply Wall St's valuation check scores only 1 out of 6, explicitly flagging high P/E multiples as a red flag for investors.
Diversified Trust Co significantly reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 45.7% during the first quarter, selling 16,910 shares to hold a remaining stake of 20,057 shares valued at $1.6 million. While Diversified Trust exited substantially, several other institutional investors including JPL Wealth Management, MV Capital Management, and Kemnay Advisory Services initiated new positions in the fourth quarter, with stakes ranging from approximately $25,000 to $28,000 each.
Insider trading activity shows a notable reduction in executive ownership. VP Donald E. Bobo, Jr. sold 23,145 shares for roughly $2 million on May 27th, while CFO Scott B. Ullem sold 13,000 shares for about $1 million in April under a pre-arranged trading plan. Collectively, insiders have sold over 81,000 shares worth approximately $6.7 million in the last ninety days, leaving them with just 0.31% of the company's stock.
Financially, Edwards Lifesciences reported strong quarterly results on April 23rd, beating analyst estimates with earnings per share of $0.78 versus a consensus of $0.73 and revenue of $1.65 billion, up 16.7% year-over-year. The company maintains robust balance sheet metrics with a current ratio of 4.42 and minimal debt, while providing FY 2026 EPS guidance between $2.95 and $3.05. Analysts currently expect full-year earnings of $3.00.
📉 Diversified Trust Co cut EW holdings by 45.7% to $1.6M stake.
💰 Insiders sold 81,038 shares worth $6.7M in last 90 days.
🏆 Company beat Q1 estimates with $0.78 EPS and $1.65B revenue.
📈 FY 2026 guidance raised to $2.95-$3.05 EPS range.
💵 Stock trades at 45.59 PE ratio with $49.36B market cap.
📉 Diversified Trust Co decreased its EW holdings by 45.7% in Q1, reducing its stake to 20,057 shares valued at $1.6 million.
📈 Multiple new institutional investors entered positions in Q4, including JPL Wealth Management ($25k), MV Capital ($26k), and Kohmann Bosshard ($28k).
💰 VP Donald E. Bobo, Jr. sold 23,145 shares for $2 million on May 27th, reducing his personal ownership by 19%.
📉 CFO Scott B. Ullem sold 13,000 shares for $1.04 million in April under a Rule 10b5-1 trading plan.
📊 Insiders have collectively sold 81,038 shares worth $6.7 million over the last ninety days.
🏆 The company beat Q1 earnings estimates with $0.78 EPS and revenue of $1.65 billion, a 16.7% increase from the prior year.
📈 Edwards Lifesciences raised FY 2026 guidance to an EPS range of $2.95-$3.05.
💵 The stock trades at a PE ratio of 45.59 with a market capitalization of $49.36 billion.
🛡️ Financial health remains strong with a current ratio of 4.42 and a debt-to-equity ratio of only 0.06.
Bullish Signals
EPS beat: $0.78 vs $0.73 consensus.
Revenue grew 16.7% to $1.65 billion.
FY 2026 EPS guidance: $2.95-$3.05.
Current ratio of 4.42 and debt-to-equity of 0.06.
Institutional inflows from JPL Wealth and MV Capital.
Risk Factors
Diversified Trust Co reduced position by 45.7% in Q1.
VP Bobo sold $2M; CFO Ullem sold $1M recently.
Total insider selling hit $6.7M over last 90 days.
Bullish Signals
Edwards Lifesciences beat Q1 analyst estimates, reporting $0.78 EPS compared to the consensus of $0.73.
Revenue grew 16.7% year-over-year to reach $1.65 billion, exceeding expectations of $1.60 billion.
The company provided forward guidance for FY 2026 EPS between $2.95 and $3.05, aligning with or slightly beating analyst consensus.
Strong balance sheet metrics include a current ratio of 4.42 and a negligible debt-to-equity ratio of 0.06.
New institutional capital is flowing in from multiple funds including JPL Wealth Management and MV Capital Management.
Risk Factors
Diversified Trust Co, a significant holder, reduced its position by 45.7% during the first quarter.
Executive insiders have sold a substantial amount of stock recently, with VP Bobo selling $2 million worth and CFO Ullem selling $1 million worth.
Total insider selling over the last ninety days reached $6.7 million, representing a 0.31% ownership stake remaining for executives.
Fisher Funds Management LTD reduced its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 31.8% during the first quarter, selling 242,305 shares. The firm now holds 519,594 shares, valued at $41.6 million, representing 1.2% of its portfolio and ranking as the 25th largest holding. Despite this reduction, several other institutional investors increased their stakes in the fourth quarter, including Hsbc Holdings PLC, which raised its position by 0.7% to own over 2.14 million shares valued at $183.19 million.
Analyst sentiment remains largely positive with multiple firms upgrading ratings or raising price targets. Wolfe Research upgraded the stock to 'outperform' with a $92 target, while Mizuho and Royal Bank of Canada also issued 'outperform' ratings with targets of $95 and $100 respectively. The consensus average price target stands at $95.96 based on 27 analysts, with the majority assigning Buy or Strong Buy ratings to the medical technology company.
Financially, Edwards Lifesciences reported strong quarterly results with revenue of $1.65 billion, beating estimates by $50 million and showing a 16.7% year-over-year increase. The company posted earnings per share of $0.78 versus a consensus of $0.73, achieving a net margin of 17.39%. Management provided guidance for FY 2026 EPS between $2.95 and $3.05, with Q2 2026 expected to range from $0.70 to $0.76.
Insider trading activity shows some selling pressure as SVP Andrew Dahl and VP Donald Bobo sold shares totaling over $2 million in May. Over the last quarter, insiders collectively sold 81,038 shares valued at approximately $6.68 million, though they still retain a small direct ownership stake of 0.31%. The company maintains a robust balance sheet with a current ratio of 4.42 and minimal debt-to-equity of 0.06.
📉 Fisher Funds sold 242,305 shares, reducing stake by 31.8%.
💰 Q1 revenue hit $1.65 billion, beating estimates by $50 million.
📊 EPS reached $0.78, surpassing the $0.73 consensus estimate.
🔮 Management guided FY 2026 EPS between $2.95 and $3.05.
🏆 Wolfe Research upgraded stock to 'outperform' with $92 target.
📉 Fisher Funds Management LTD sold 242,305 shares of Edwards Lifesciences in Q1, reducing its stake by 31.8% to 519,594 shares.
📈 Hsbc Holdings PLC increased its position by 0.7% to own 2.14 million shares valued at $183.19 million during the fourth quarter.
🏆 Wolfe Research upgraded Edwards Lifesciences to 'outperform' with a $92 price target, while Royal Bank of Canada set a $100 target.
💰 The company reported Q1 revenue of $1.65 billion, beating analyst estimates by $50 million and growing 16.7% year-over-year.
📊 Edwards Lifesciences posted earnings per share of $0.78, surpassing the consensus estimate of $0.73 with a 17.39% net margin.
🔮 Management guided FY 2026 EPS between $2.95 and $3.05, indicating continued growth expectations for the fiscal year.
📉 Insiders sold 81,038 shares valued at $6.68 million in the last quarter, with VP Donald Bobo reducing his stake by 19%.
💵 The stock trades at a P/E ratio of 46.55 with a market capitalization of $50.39 billion and a beta of 0.87.
🏥 Edwards Lifesciences focuses on structural heart disease therapies, including the SAPIEN family of transcatheter heart valves.
📉 The stock opened at $87.51, trading above its 50-day moving average of $83.39 but below its 200-day average of $83.13.
Bullish Signals
EPS beat estimates at $0.78 vs $0.73 consensus.
Revenue surged 16.7% to $1.65 billion.
Analysts upgraded stock with RBC setting $100 target.
Strong balance sheet: current ratio 4.42, debt-to-equity 0.06.
Institutional investors increased stakes in the business.
Risk Factors
Insiders sold 81,038 shares worth $6.68 million last quarter.
Fisher Funds reduced position by 31.8% selling 242,305 shares.
Bullish Signals
Edwards Lifesciences beat Q1 earnings estimates with EPS of $0.78 versus the consensus of $0.73, demonstrating strong operational performance.
Revenue reached $1.65 billion in the quarter, representing a significant 16.7% increase compared to the same period last year.
Multiple analysts have upgraded the stock or raised price targets, with Royal Bank of Canada setting a high $100 target and Wolfe Research issuing an 'outperform' rating.
The company maintains a very strong balance sheet with a current ratio of 4.42 and a negligible debt-to-equity ratio of 0.06.
Institutional investors like Hsbc Holdings PLC and Corient Private Wealth LLC increased their stakes, signaling continued confidence in the business model.
Risk Factors
Insiders sold a total of 81,038 shares valued at $6.68 million over the last quarter, indicating some internal profit-taking or portfolio rebalancing.
Fisher Funds Management LTD significantly reduced its position by 31.8% in Q1, selling 242,305 shares which may reflect a change in institutional sentiment.
Edwards Lifesciences (EW) is currently trading at $86.28, with full-year revenue of $6.3 billion and net income of $1.07 billion. The article argues the stock is undervalued by 11%, suggesting a fair value of $96.92 based on growth assumptions tied to its cardiovascular portfolio. However, valuation metrics present a mixed picture, as the current P/E ratio of 46.2x significantly exceeds the US Medical Equipment industry average of 24.5x and peer average of 25.1x.
The primary bullish drivers include the anticipated approval of an early TAVR indication in the second quarter and policy changes that could expand revenue streams globally. Additionally, the planned 2024 launch of the transcatheter tricuspid valve EVOQUE is expected to position Edwards as a market leader, potentially increasing its share in this new therapy area.
Despite the upside potential, risks remain regarding tariffs impacting margins and competition limiting growth in TAVR procedures. The article concludes that while the fair value model suggests undervaluation, investors must weigh these concerns against the high current multiple to determine if expectations are sustainable.
📈 EW trades at $86.28, implying 11% undervaluation vs $96.92 fair value.
💰 Full-year revenue hit $6,303.5M with net income of $1,075.6M.
🚀 Early TAVR approval expected in Q2 to drive future growth.
🔬 EVOQUE tricuspid valve therapy launches in 2024 as first-in-class.
⚖️ P/E ratio of 46.2x exceeds industry average of 24.5x.
📈 Edwards Lifesciences (EW) trades at $86.28 with a calculated fair value of $96.92, implying an 11% undervaluation.
💰 The company reported full-year revenue of $6,303.5 million and net income of $1,075.6 million.
🚀 An early TAVR indication is expected to receive approval in the second quarter, driving future growth.
🔬 The transcatheter tricuspid valve EVOQUE is scheduled for launch in 2024 as a first-in-class therapy.
⚖️ Current P/E ratio of 46.2x is significantly higher than the industry average of 24.5x and peer average of 25.1x.
⚠️ Tariffs could negatively impact profit margins if they weigh heavily on operations.
🏥 Competition may limit expected growth rates in the TAVR procedure market.
Bullish Signals
Undervalued by 11% with $96.92 fair value target.
Risk Factors
P/E ratio of 46.2x exceeds industry average of 24.5x.
High valuation leaves little room for error if expectations fail.
Tariffs could heavily weigh on margins and pressure profitability.
Competition may limit expected growth in TAVR procedures.
Bullish Signals
The stock is modeled as undervalued by 11% with a fair value target of $96.92 versus the current price of $86.28.
Upcoming approval for an early TAVR indication in Q2 represents a significant multi-year growth opportunity.
Global policy and guideline changes are expected to enhance revenue streams for the company's cardiovascular portfolio.
The 2024 launch of the EVOQUE tricuspid valve will make Edwards the first company to offer this specific therapy, aiding market share gains.
Recent shareholder returns have been positive, with a 15.32% total return over the past year.
Risk Factors
The current P/E ratio of 46.2x is well above the US Medical Equipment industry average of 24.5x and peer average of 25.1x.
High valuation multiples suggest the market may already be pricing in future growth, leaving less room for error if expectations are challenged.
Tariffs could weigh heavily on margins, potentially pressuring profitability.
Competition could limit the expected growth in TAVR procedures.
Public Employees Retirement Association of Colorado dramatically increased its stake in Edwards Lifesciences (NYSE: EW) by 1,037.2% in the fourth quarter, purchasing an additional 779,187 shares to hold a total position valued at approximately $72.8 million. This significant move brings institutional ownership to 79.46%, while several other hedge funds also modestly raised their positions during the same period.
Edwards Lifesciences reported strong quarterly financial results with earnings per share of $0.78 and revenue of $1.65 billion, both exceeding analyst estimates. The company maintains a Moderate Buy consensus among analysts with an average price target of $95.96, supported by recent upgrades from firms like Wolfe Research and BTIG.
Despite the positive institutional activity and earnings beat, the article notes that insiders, including the VP and CFO, sold shares recently under pre-arranged trading plans. Additionally, MarketBeat explicitly states that EW was not included in their list of five preferred healthcare stocks for growth-minded investors, suggesting relative weakness compared to other sector picks.
📈 PERA stake surged 1,037.2% to $72.8 million.
💰 Q4 EPS hit $0.78, beating estimates.
📊 Institutional ownership stands at 79.46%.
📉 Executives sold shares under Rule 10b5-1 plans.
🎯 Analysts rate it Moderate Buy with $95.96 target.
📈 Public Employees Retirement Association of Colorado increased its stake by 1,037.2% to own 854,314 shares valued at $72.8 million.
💰 The company reported Q4 EPS of $0.78 and revenue of $1.65 billion, beating consensus estimates.
📊 Institutional investors now hold 79.46% of the company's outstanding stock.
📉 VP Daniel J. Lippis sold 1,019 shares and CFO Scott B. Ullem sold 13,000 shares recently under Rule 10b5-1 plans.
🎯 Analysts maintain a Moderate Buy consensus with an average price target of $95.96.
📉 MarketBeat explicitly lists five other healthcare stocks as better buys than Edwards Lifesciences.
🏥 The company focuses on structural heart disease products, including the SAPIEN family of transcatheter valves.
📈 FY 2026 EPS guidance is set between $2.95 and $3.05.
Bullish Signals
PERA increased stake by 1,037.2%.
Beat EPS to $0.78 with $1.65B revenue.
Revenue grew 16.7% year-over-year.
Hedge funds increased holdings significantly.
Analysts target $95.96 with Moderate Buy consensus.
Risk Factors
Insiders sold 81,038 shares worth $6.68 million recently.
MarketBeat excludes Edwards Lifesciences from preferred healthcare growth stocks.
Stock trades below consensus price target of $95.96.
Bullish Signals
Public Employees Retirement Association of Colorado executed a massive 1,037.2% stake increase, signaling strong institutional confidence.
The company beat earnings estimates with $0.78 EPS and revenue of $1.65 billion.
Revenue grew 16.7% year-over-year to $1.65 billion.
Multiple hedge funds including Level Four Advisory Services LLC and McIlrath & Eck LLC increased their holdings.
Analysts maintain a Moderate Buy consensus with an average price target of $95.96.
Recent analyst upgrades from Wolfe Research, BTIG, and Mizuho reinforce positive sentiment.
Risk Factors
Insiders sold a total of 81,038 shares worth $6.68 million in the last three months.
MarketBeat explicitly states that Edwards Lifesciences was not included in their list of five preferred healthcare stocks for growth investors.
The stock is currently trading below its consensus price target of $95.96.
Edwards Lifesciences Corp. has received FDA approval for its Triformis Resilia tricuspid valve, marking the first and only surgical valve specifically designed for patients with tricuspid valve disease. The Irvine-based medical device manufacturer secured premarket approval last year and plans to launch the product in the U.S. during the second half of 2026. Following the announcement, Edwards shares fell 1% to $86.65, reflecting a market capitalization of approximately $49.8 billion on the NYSE under ticker EW. The approval represents a significant milestone for the company's expansion into the tricuspid valve treatment market, addressing a specific unmet need in cardiac care.
🏥 FDA approved Triformis Resilia as the first surgical tricuspid valve.
📅 U.S. launch scheduled for the second half of 2026.
💰 Shares dipped 1% to $86.65 despite the approval news.
🏥 Edwards Lifesciences received FDA approval for the Triformis Resilia tricuspid valve.
🔬 The device is marketed as the first and only surgical valve specifically designed for the tricuspid position.
📅 The company plans to launch the product in the U.S. during the second half of 2026.
📉 Edwards shares fell 1% to $86.65 following the approval news.
💰 The company's market capitalization stands at approximately $49.8 billion.
🏢 Edwards Lifesciences is headquartered in Irvine, California.
📝 The device received premarket approval last year before this week's final FDA clearance.
Bullish Signals
FDA approved Edwards Lifesciences Triformis Resilia for tricuspid valve disease.
First and only surgical valve designed specifically for tricuspid position.
U.S. launch planned for second half of 2026.
Risk Factors
Shares fell 1% to $86.65 after FDA approval.
Negative sentiment persists despite major regulatory milestone.
Bullish Signals
Edwards Lifesciences Corp. secured FDA approval for Triformis Resilia, a surgical valve specifically designed for patients with tricuspid valve disease.
The company positions Triformis Resilia as the first and only surgical valve of its kind for the tricuspid position, highlighting its unique market differentiation.
Edwards is planning a U.S. launch in the second half of 2026, indicating strong commercial momentum following regulatory clearance.
Risk Factors
Shares in Edwards fell 1% to $86.65 following the FDA approval announcement, indicating negative market sentiment despite the milestone.
Edwards Lifesciences has received FDA approval for the Triformis Resilia, marking the first surgical valve specifically designed and approved for the tricuspid position. Approved in May 2026, the device addresses a long-standing unmet need where surgeons previously had to use mitral valves for tricuspid replacements due to a lack of dedicated options. The company plans to launch the Triformis Resilia in the second half of 2026.
The valve features a purpose-built sewing ring with a flattened section along the septal region, designed to mimic native tricuspid anatomy and avoid disruption of the atrioventricular (AV) node located near the septal leaflet. Edwards states that pre-clinical studies demonstrated no significant conduction abnormalities or structural dysfunction, alongside optimal seating performance. The device utilizes Resilia bovine pericardial tissue leaflets attached to a lightweight nitinol wireform, which allows for 55-degree folding during implantation to prevent suture looping.
The Triformis Resilia is available in five sizes ranging from 25 mm to 33 mm and incorporates Edwards Integrity Preservation technology for the tissue leaflets. This technology uses glycerol-based dry storage instead of glutaraldehyde solutions to reduce calcification and pannus while enhancing durability and hemodynamic performance. The valve includes specific orientation markings, such as an 'S' on the septal segment, to assist surgeons during implantation.
✅ FDA approved May 2026 as first dedicated surgical tricuspid valve.
🔧 Flattened septal ring design prevents AV node disruption during implantation.
🦴 Features Resilia tissue tech with foldable nitinol frame and five sizes.
🏥 Edwards Lifesciences received FDA approval in May 2026 for the Triformis Resilia, the first surgical valve specifically designed and approved for the tricuspid position.
🔧 The device features a critical design change: a flattened sewing ring along the septal region to match native tricuspid anatomy and avoid AV node disruption.
⚠️ Previously, surgeons used mitral valves for tricuspid replacements because no dedicated surgical tricuspid valves were approved due to market size and clinical study challenges.
🦴 The valve utilizes Edwards' Resilia tissue technology with three bovine pericardial leaflets attached to a lightweight nitinol wireform frame.
📐 Triformis is available in five sizes ranging from 25 mm to 33 mm to accommodate various patient anatomies.
🧬 The nitinol wireform allows the stent posts to fold 55° during implantation, which helps avoid suture looping and facilitates placement.
🛡️ A cobalt-chromium alloy band and a polyester band provide structural support for the valve's orifice below the wireform.
📍 Orientation markings on the sewing ring include black lines for commissures and letters 'A' and 'S' to identify anterior and septal segments.
🧪 The sewing ring is made of compliant silicone-rubber covered with porous PTFE cloth to facilitate tissue ingrowth and encapsulation.
🛡️ Edwards Integrity Preservation technology uses glycerol-based dry storage instead of glutaraldehyde to reduce calcification and eliminate residual aldehyde groups.
📉 Pre-clinical studies demonstrated no significant conduction abnormalities, optimal seating, and good hemodynamic performance with leaflet mobility.
🚀 Edwards plans to launch the Triformis Resilia valve in the second half of 2026 to address this long-underserved area of structural heart care.
Bullish Signals
FDA approved May 2026 for first dedicated tricuspid surgical valve.
Addresses unmet need replacing mitral valves for tricuspid replacements.
No conduction abnormalities or AV node disruption in pre-clinical studies.
Integrity Preservation tech enhances durability and hemodynamic performance.
Launch planned second half 2026 expanding Resilia portfolio.
Risk Factors
Small market limits revenue.
Clinical study challenges persist.
No dedicated surgical tricuspid valves exist.
Surgeons use mitral valves instead.
Bullish Signals
Edwards Lifesciences received FDA approval in May 2026 for the Triformis Resilia, becoming the first surgical valve specifically designed and approved for the tricuspid position.
The new valve introduces a purpose-built option for a long-underserved area of structural heart care, addressing an unmet patient need where surgeons previously had to use mitral valves for tricuspid replacements.
Pre-clinical studies demonstrated no significant conduction abnormalities and optimal seating, effectively avoiding AV node disruption which can cause abnormal heart rhythms.
The valve features Edwards Integrity Preservation technology that reduces calcification and pannus while enhancing durability and hemodynamic performance through dry storage methods.
Edwards plans to launch the Triformis Resilia valve in the second half of 2026, expanding its Resilia tissue technology portfolio to the tricuspid position.
Risk Factors
The article notes that manufacturers have not innovated on dedicated surgical tricuspid valves due to a 'relatively small market' and 'challenges in conducting prospective clinical studies', which may limit the potential revenue upside for this new product.
Edwards Lifesciences states that surgeons previously had to use mitral valves for tricuspid replacements because there were no approved dedicated options, indicating a historical lack of innovation in this specific anatomical area.
Analysts from TD Cowen provided new ratings on healthcare stocks P3 Health Partners (PIII) and Edwards Lifesciences (EW). Ryan Langston assigned a Hold rating to P3 Health Partners with a price target of $14.00, while Josh Jennings maintained a Buy rating on Edwards Lifesciences with the company's shares closing at $83.20. The consensus for Edwards Lifesciences remains Strong Buy with an average price target of $97.86, representing 19.2% upside from current levels. For P3 Health Partners, the analyst consensus is Moderate Buy with a price target of $14.00, which is a 38.5% upside from current levels.
📊 TD Cowen holds P3 Health at $14 despite 38% consensus upside potential.
💰 Edwards Lifesciences trades below $97.86 Street target with Strong Buy consensus.
⚠️ Analyst track records show mixed results for healthcare sector picks.
📊 Analyst Ryan Langston from TD Cowen assigned a Hold rating to P3 Health Partners (PIII) with a price target of $14.00.
💰 The company's shares closed last Thursday at $13.86, just below the analyst's target.
📉 Langston's historical track record shows an average return of -4.8% and a 38.6% success rate on his Healthcare sector picks.
🤝 P3 Health Partners currently holds a Moderate Buy consensus with a $14.00 average price target representing 38.5% upside.
⚠️ A previous report from TipRanks – Anthropic upgraded the stock to Hold with a lower $3.50 price target on May 9.
🩺 Analyst Josh Jennings from TD Cowen maintained a Buy rating on Edwards Lifesciences (EW).
💵 Edwards Lifesciences shares closed last Thursday at $83.20, well below the general street consensus of $97.86.
📈 The Street generally suggests a Strong Buy consensus for Edwards Lifesciences with an average price target of $97.86.
🔝 This represents a 19.2% upside potential from current levels according to the aggregated analyst data.
🔄 A prior report from TipRanks – PerPlexity reiterated a Buy rating on Edwards Lifesciences with a $96.00 price target.
🏥 Both analysts cover the Healthcare sector, with Jennings also tracking companies like Anteris Technologies and Orchestra BioMed.
📰 Additional headlines note P3 Health Partners' trading halt, earnings call signals for a turnaround, and recent debt exchange execution.
📉 Lake Street previously raised its price target for P3 Health Partners to $14 from $4.
Bullish Signals
P3 Health Partners has Moderate Buy consensus with $14 target (38.5% upside).
TD Cowen maintains Buy on Edwards, reinforcing positive outlook.
Risk Factors
Analyst Ryan Langston holds P3 Health Partners at $14 target vs $13.86 close.
TD Cowen's Josh Jennings has 0% avg return and 43.8% Edwards Lifesciences success.
Bullish Signals
P3 Health Partners has an analyst consensus of Moderate Buy with a price target of $14.00, representing a 38.5% upside from current levels.
Lake Street recently raised the price target for P3 Health Partners to $14 from $4, indicating significant positive sentiment.
Edwards Lifesciences maintains a Strong Buy analyst consensus rating with an average price target of $97.86, offering a 19.2% upside potential.
TD Cowen analyst Josh Jennings maintained a Buy rating on Edwards Lifesciences, reinforcing the stock's positive outlook.
Risk Factors
Analyst Ryan Langston assigned a Hold rating to P3 Health Partners with a price target of $14.00, while the company's shares closed at $13.86.
Analyst Josh Jennings from TD Cowen maintained a Buy rating on Edwards Lifesciences, but his personal track record shows an average return of 0.0% and a 43.8% success rate.
Edwards Lifesciences (EW) has released its first-quarter 2024 financial results and updated its full-year outlook for 2025, maintaining investor focus on growth within transcatheter heart valves and structural heart therapies. The company reported total sales in the mid-single-digit percentage range compared to the prior-year period, with its branded transcatheter aortic valve replacement (TAVR) systems serving as the primary revenue driver. This core business targets older patients with severe aortic stenosis who are at elevated risk from conventional open-heart surgery, benefiting from demographic trends such as aging populations in the United States and Europe, as well as expanding clinical guidelines that extend TAVR eligibility to lower-risk patients.
Beyond its dominant TAVR segment, Edwards is seeing steady momentum in transcatheter mitral and tricuspid therapies, which are growing from a low base as new devices progress through regulatory pathways and clinical data accumulate. The company also maintains a significant portfolio of surgical heart valves and repair products used in open-heart procedures, providing stable cash flows that complement the faster-growing catheter-based interventions. Additionally, its critical care segment offers hemodynamic monitoring solutions for intensive care units and operating rooms, generating recurring revenue through consumable components and software updates that are less dependent on high-ticket procedure volumes.
Strategically, Edwards differentiates itself from diversified medtech peers by concentrating exclusively on technologies for structural heart disease and critical care monitoring, with a heavy emphasis on research and development to expand indications and improve device performance. The company is investing heavily in clinical trials for next-generation platforms aimed at extending device durability and safety, which are crucial for physician adoption and reimbursement decisions. While competition in the structural heart device market has intensified due to multiple approved valve systems leading to price pressure in some regions, Edwards continues to focus on differentiation through superior clinical outcomes and advanced device features to maintain its market position.
📈 Q1 2024 total sales grew mid-single-digits year-over-year.
❤️ TAVR remains the core driver targeting severe aortic stenosis.
🔬 R&D investments expand indications and improve device performance.
👴 Aging demographics sustain demand for heart valve interventions.
🛡️ Long-term data drives physician adoption and reimbursement decisions.
📈 Edwards Lifesciences reported mid-single-digit percentage growth in total sales for Q1 2024 compared to the prior-year period.
❤️ The company's core revenue driver is transcatheter aortic valve replacement (TAVR), which targets older patients with severe aortic stenosis.
🔬 Edwards focuses on minimally invasive technologies that reduce recovery time and hospital stays compared to traditional open-heart surgery.
💊 Beyond TAVR, the company develops surgical heart valves, repair products, and therapies for mitral and tricuspid valve regurgitation.
🏥 The critical care segment provides hemodynamic monitoring solutions used in intensive care units and operating rooms.
📉 While surgical structural heart product growth is slower than transcatheter therapies, it offers stable cash flows to complement high-ticket procedures.
🔍 Edwards reinvests a substantial share of revenue into research and development to expand indications and improve device performance.
⚖️ The company competes in a market with high entry barriers due to rigorous regulatory standards and complex manufacturing requirements.
📉 Intense competition from other medtech companies has led to price pressure, prompting a focus on differentiation through clinical outcomes.
👴 Demographic trends such as aging populations in the US and Europe continue to support industry demand for heart valve interventions.
🔬 Edwards is conducting ongoing studies in mitral and tricuspid valve disease to address patient populations with limited treatment options.
📊 The company's strategy emphasizes innovation based on clinical evidence to support new product approvals and long-term growth.
🛡️ Long-term data on valve performance influences physician adoption and reimbursement decisions by health systems and insurers.
🌍 Edwards positions itself as a comprehensive partner for cardiac surgeons by offering both surgical and catheter-based intervention portfolios.
💰 The critical care business is recurring in nature due to consumable components and software updates, creating a complementary revenue stream.
Bullish Signals
Q1 2024 sales grew mid-single-digits driven by TAV therapies.
TMC and TVT therapies show steady momentum from low bases.
Substantial R&D reinvestment supports new approvals and long-term growth.
Long-term valve data risks adoption and reimbursement.
Heavy R&D reinvestment may hurt short-term profitability.
Bullish Signals
Edwards Lifesciences reported mid-single-digit percentage growth in total sales for Q1 2024, with transcatheter aortic valve therapies driving the largest segment contribution.
The company is seeing steady momentum in transcatheter mitral and tricuspid therapies from a low base as clinical data accumulate and new devices progress through regulatory pathways.
Edwards Lifesciences reinvests a substantial share of revenue into research and development to support new product approvals and long-term growth, according to its 2023 annual report.
The company's comprehensive portfolio covering both surgical and catheter-based interventions supports stable cash flows even as practice patterns evolve in the structural heart market.
Edwards Lifesciences is investing heavily in clinical trials and next-generation platforms to extend device durability and safety, aiming to expand its addressable market if trial outcomes are favorable.
Industry demand is supported by demographic trends such as aging populations in the United States and Europe, which continues to increase the number of patients eligible for heart valve interventions.
Risk Factors
Total sales growth in Q1 2024 was only in the mid-single-digit percentage range, indicating a slowdown compared to prior-year periods.
Intensified competition from multiple approved TAVR platforms in the US and Europe is creating price pressure in some markets.
Growth in surgical structural heart products is generally slower than in transcatheter therapies, limiting diversification benefits.
Long-term data on valve performance can negatively influence physician adoption and reimbursement decisions by health systems and insurers.
The company's strategy relies heavily on reinvesting a substantial share of revenue into R&D and clinical studies, which may impact short-term profitability.
Edwards Lifesciences is positioned as a leading provider of heart valve technologies and critical care monitoring solutions, with its stock recently drawing investor attention following quarterly results released in late April 2026. The company specializes in treating patients with severe heart valve conditions, particularly those who are elderly or considered high-risk for open-heart surgery, by utilizing minimally invasive transcatheter aortic valve replacement (TAVR) procedures that allow for shorter hospital stays. Revenue generation is driven primarily by its TAVR portfolio, which includes devices delivered via catheters through the femoral artery, as well as a complementary line of surgical heart valves for patients who undergo open-heart surgery due to age or anatomical factors.
Beyond its valve portfolios, Edwards Lifesciences diversifies income through critical care technologies, specifically advanced hemodynamic monitoring systems used in operating rooms and intensive care units. These platforms provide real-time data on cardiac output and fluid status, contributing recurring revenue via disposables and system upgrades. The company sells these products primarily to hospitals and heart centers across North America, Europe, and select Asia-Pacific markets through direct sales teams and distributors, navigating a highly regulated environment that necessitates substantial investment in clinical trials and physician training programs.
The firm's growth trajectory remains closely tied to the expanding adoption of TAVR procedures over the past decade and the demographic shift toward aging populations in the United States and Europe who require these interventions. Despite operating in a competitive landscape with high barriers to entry, Edwards Lifesciences maintains a strategic focus on offering comprehensive therapy options that allow clinicians to select appropriate treatments for specific patient profiles, while ongoing developments in reimbursement dynamics and technology adoption continue to influence its valuation and earnings potential.
🏥 Edwards focuses on TAVR for elderly patients via minimally invasive catheter procedures.
💉 Critical care monitoring and surgical valves provide diversification and recurring revenue streams.
📈 Aging demographics drive growth, while high regulations ensure sustainable market entry.
🏥 Edwards Lifesciences recently reported quarterly results and updated guidance, keeping it in focus for US healthcare investors.
❤️ The company specializes in structural heart therapies, particularly transcatheter aortic valve replacement (TAVR) for elderly and high-risk patients.
💉 Its main product line involves minimally invasive valves delivered via catheters, which reduces recovery time compared to open-heart surgery.
🔬 Edwards also supplies critical care monitoring technologies in hospitals that track hemodynamic parameters during complex procedures.
🌍 The company sells primarily through direct sales teams and distributors across North America, Europe, and parts of Asia-Pacific.
⚠️ High regulatory standards create entry barriers but require significant investment in clinical trials and physician training programs.
📈 TAVR remains the largest revenue contributor, driven by a decade-long growth trend in transcatheter procedures.
✂️ Traditional surgical heart valves serve younger patients or those with anatomical factors favoring open surgery, providing portfolio diversification.
🩺 Critical care monitoring systems contribute recurring revenue through disposables and upgrades, stabilizing overall earnings.
👴 Growth is closely linked to demographic trends in aging populations and expanding treatment options in key markets.
📉 Investors must consider competitive market dynamics, innovation costs, and reimbursement changes when evaluating the stock's long-term value.
📊 Recent commentary from financial media outlets like Reuters highlights continued attention on the company's structural heart therapy advancements.
Bullish Signals
TAVR growth drives revenue for elderly and high-risk patients.
Minimally invasive procedures shorten hospital stays versus open surgery.
Critical care platforms generate recurring revenue from disposables and upgrades.
Demographic trends fuel procedure adoption across US, Europe, and APAC.
Risk Factors
High regulated barriers drive significant ongoing development costs.
Slow valve growth limits diversification if open-heart demand drops.
Critical care lack of growth creates business concentration risk.
Earnings exposure to potential US and Europe policy changes.
Substantial resources required for trials and training.
Bullish Signals
Edwards Lifesciences highlighted ongoing growth in transcatheter aortic valve replacement (TAVR) and other structural heart therapies, driving revenue from products used for elderly and high-risk patients.
The company's minimally invasive TAVR procedures shorten hospital stays compared with conventional open-heart surgery, offering a clear value proposition to healthcare providers.
Critical care monitoring platforms provide clinicians with real-time data during complex procedures, contributing recurring revenue through disposables and system upgrades.
Edwards Lifesciences benefits from favorable demographic trends and continued adoption of heart valve procedures in aging populations across the US, Europe, and Asia-Pacific markets.
The firm maintains a strong global presence in North America, Europe, and selected Asia-Pacific markets, supported by high barriers to entry due to rigorous clinical trials and regulatory compliance.
Risk Factors
The company incurs significant ongoing development costs due to high barriers to entry in the highly regulated medical device industry.
Revenue from surgical heart valves is growing slower than the TAVR portfolio, potentially limiting diversification benefits if demand for open-heart procedures declines.
While critical care technologies provide recurring revenue, this segment lacks the same strong growth narrative as the core TAVR business, which may lead to concentration risk.
Company earnings and valuation are heavily dependent on continued reimbursement dynamics in the US and Europe, creating exposure to potential policy changes.
The company must continue allocating substantial resources to clinical trials and physician training programs to maintain its market position against competitors.
Edwards Lifesciences has released long-term durability data from the COMMENCE aortic trial, focusing specifically on its RESILIA tissue technology. Announced at the 106th American Association for Thoracic Surgery Annual Meeting in Singapore, these findings highlight the performance of Edwards' surgical valves after a decade of use. At the 10-year mark, patients treated with these valves demonstrated a 97.9% freedom from structural valve deterioration (SVD) and a 97.8% freedom from reoperation specifically due to SVD. Additionally, the trial showed a 98.6% freedom from non-structural valve dysfunction, excluding paravalvular leak, alongside sustained hemodynamic performance characterized by stable gradients and effective orifice area over time.
Vikram Jaisinghani, Senior Director of Medical Affairs for Asia-Pacific at Edwards Lifesciences, emphasized that extending the evidence base to 10 years supports the long-term durability and performance of the RESILIA tissue, which is crucial for lifetime management of patients with aortic stenosis. Dato' Seri Dr. Jeffrey Jeswant Dillon, a Senior Consultant Cardiothoracic Surgeon at Institut Jantung Negara in Kuala Lumpur, noted that as bioprosthetic valves are increasingly used in younger and lower-risk patients who wish to avoid anticoagulation, long-term durability is now a central consideration in surgical decision-making due to increasing life expectancy. He stated that the minimal structural valve deterioration observed provides clinicians with confidence for long-term treatment planning.
The RESILIA tissue technology was developed over two decades ago to address the need for improved durability in bioprosthetic valves and is now incorporated across Edwards' surgical and transcatheter platforms for aortic and mitral procedures. Amit Raheja, Senior Vice President of Asia-Pacific at Edwards Lifesciences, stated that these advancements underscore the company's commitment to pioneering innovation in the region. He noted that the availability of robust 10-year clinical data helps ensure clinicians in the Asia-Pacific region can make informed treatment decisions that benefit patients over their lifetime. Edwards reports that more than 500,000 patients worldwide have been treated with its innovations featuring RESILIA tissue, including over 30,000 in the Asia-Pacific region alone.
🏥 Edwards announced 10-year trial results showing high durability for RESILIA tissue in Singapore.
📉 Patients achieved 97.9% freedom from structural valve deterioration and stable hemodynamic performance at 10 years.
💔 These findings support lifetime management for the growing Asia-Pacific population facing valvular heart disease.
🏥 Edwards Lifesciences announced 10-year results from the COMMENCE aortic trial, highlighting the long-term durability of its RESILIA tissue.
📍 The findings were presented at the 106th American Association for Thoracic Surgery Annual Meeting in Singapore.
💔 Valvular heart disease represents a significant and growing burden on healthcare systems across the Asia-Pacific region.
⏳ Extended evidence to 10 years further supports the long-term durability and performance of RESILIA tissue for lifetime patient management.
📉 At 10 years, patients with Edwards surgical valves featuring RESILIA tissue experienced 97.9% freedom from structural valve deterioration (SVD).
✋ Patients also achieved 97.8% freedom from reoperation due to SVD and 98.6% freedom from non-structural valve dysfunction.
💓 The trial demonstrated sustained hemodynamic performance, including stable gradients and effective orifice area over time.
👥 Minimal structural valve deterioration at 10 years provides confidence for long-term treatment planning and may reduce the need for repeat interventions.
🔄 Long-term durability is becoming central to surgical decision-making as bioprosthetic valves are increasingly used in younger, active patients with higher life expectancies.
🧬 RESILIA tissue technology was developed over two decades ago to address improved durability needs and is now incorporated across Edwards' surgical and transcatheter platforms.
🌏 To date, more than 500,000 patients worldwide, including over 30,000 in the Asia-Pacific region, have been treated with RESILIA tissue innovations.
🤝 The COMMENCE trial builds on a strong body of evidence, including large randomized FDA-approved studies such as the PARTNER series.
🌏 Edwards aims to invest in clinical evidence and regional capabilities to support sustainable growth and improved patient care across Asia-Pacific.
🔬 Over 500,000 patients worldwide have been treated with innovations featuring RESILIA tissue based on cumulative internal sales data.
Bullish Signals
97.9% freedom from structural deterioration at 10 years.
98.6% freedom from non-structural dysfunction sustained over time.
Over 500,000 patients treated worldwide with RESILIA valves.
30,000 procedures completed in the Asia-Pacific region.
Supports durable valve need for younger Asian patients.
Risk Factors
No financial risks mentioned.
No competitive threats discussed.
No regulatory concerns raised.
Text is overly promotional.
Bullish Signals
The 10-year COMMENCE trial data revealed that 97.9% of patients treated with Edwards' RESILIA tissue valves remained free from structural valve deterioration, significantly reinforcing long-term durability.
Patients also demonstrated a 97.8% freedom rate from reoperation due to structural valve deterioration and a 98.6% freedom rate from non-structural valve dysfunction, highlighting sustained hemodynamic performance over time.
These robust clinical results support the growing need for durable valve solutions in the Asia-Pacific region, where bioprosthetic valves are increasingly used in younger patients with longer life expectancies.
To date, Edwards' RESILIA tissue technology has been successfully utilized in more than 500,000 patients worldwide, including over 30,000 procedures specifically within the Asia-Pacific region.
Risk Factors
The article focuses entirely on positive clinical trial results (97.9% freedom from structural valve deterioration) and market expansion in Asia-Pacific, with no mention of financial risks, competitive threats, or regulatory concerns.
As the text is overwhelmingly promotional with no negative elements present, no adverse points can be extracted without fabricating information.
Edwards Lifesciences is hosting an employee of the week feature on Jessica O'Grady, a 34-year-old woman with Down Syndrome from Kildimo, who has taken on a courier role at their Limerick plant. Since January, O'Grady delivers mail and parcels to every department within the facility every Thursday, completing the rounds in about 45 minutes after her shift at Edwards Life Sciences. The initiative is a collaboration between the medical device manufacturer, Down Syndrome Ireland, and Down Syndrome Limerick, aiming to support adults with disabilities in securing independent employment.
The role was offered directly by Edwards following a proactive approach rather than a standard application, as the company sought to integrate O'Grady into their workforce through their mentorship program. Nicole Maxwell, a manufacturing team lead acting as her mentor, notes that O'Grady has become familiar with the internal layout and specific employees she delivers to, including IT staff. The experience is proving beneficial for the wider community engagement, with Edwards also supporting employment programs at local businesses like hotels and Specsavers branches in other counties.
Jessica's mother, Ann O'Grady, highlights that the position has significantly improved her daughter's sense of independence and ability to integrate into the community. During a feature interview, O'Grady shared details about her previous work experience in hospital and pharmacy settings, as well as her personal interests such as Disney merchandise and coffee, which she enjoys treating herself to on payday. The story illustrates a successful public-private partnership where the company initiated the hiring process to facilitate meaningful employment opportunities for individuals with Down Syndrome.
📦 Jessica delivers parcels to Edwards Lifesciences weekly in just 45 minutes.
💼 The role supports adults with Down Syndrome through a collaborative initiative.
🗺️ A color-coded map guides her memorized route across the plant departments.
✨ Colleagues note she has grown more confident and outgoing since starting.
🏢 Similar programs now include positions at local hotels and Specsavers branches.
📦 Jessica O'Grady has taken a new role at Edwards Lifesciences in Limerick, delivering parcels to all departments every Thursday since January.
☕ The 34-year-old from Kildimo previously drank hot chocolate but now relies on coffee due to the increased energy demands of her busy schedule.
🤝 The position is a collaborative initiative between Edwards Lifesciences, Down Syndrome Limerick, and Down Syndrome Ireland to support employment for adults with Down Syndrome.
💼 Jessica has already participated in company fundraisers for Heart Month and World Epilepsy Day while using the on-site gym after her shifts.
🗺️ A mentor, Nicole Maxwell, guides Jessica through a color-coded route map that she memorized, allowing her to know staff names and table locations within IT departments.
⏱️ Jessica completes her weekly delivery of letters and parcels across the Edwards plant in an impressive 45 minutes.
🌟 Colleagues report that Jessica has become more outgoing and confident since starting the role, often sharing laughs with the team every Thursday.
💡 Jessica previously worked in hospital and pharmacy settings but was hired directly by Edwards after they approached Down Syndrome Limerick regarding her potential.
🏢 The employment program extends beyond Edwards to include positions at the Radisson Hotel, The Woodlands Hotel, and multiple Specsavers branches in the area.
👨👩👧 Jessica's mother, Ann O'Grady, notes that the role has significantly improved Jessica's independence and integration into the local community.
✨ Jessica enjoys Disney-themed treats on payday and maintains her usual coffee habit despite the professional grind.
Bullish Signals
Edwards Lifesciences hired Jessica O'Grady from Down Syndrome Ireland.
Jessica delivers parcels to departments via her custom Thursday route.
Jessica knows IT staff by name and uses the company gym.
Mentor Nicole Maxwell praised Jessica's rapid progress over weeks.
Edwards took proactive initiative for inclusive employment instead of waiting.
Risk Factors
Article contains no meaningful negative points to extract.
No specific risks identified.
No downturn metrics present.
Bullish Signals
Edwards Lifesciences successfully integrated a new employee with Down Syndrome, Jessica O'Grady, into their Limerick plant through a collaboration with Down Syndrome Ireland.
Jessica is already making an immediate positive impact, delivering parcels and letters to all departments via her custom route every Thursday.
The company environment has been so welcoming that Jessica quickly built relationships, knowing IT staff by name and regularly using the company gym after shifts.
Nicole Maxwell, a manufacturing team lead and mentor at Edwards, praised Jessica's progress, noting she has come out of herself over just a few weeks.
Edwards Lifesciences took the initiative to hire Jessica, demonstrating a proactive approach to inclusive employment by reaching out directly rather than waiting for applications.
The success of this specific role is contributing to a broader, hugely successful national employment program at Edwards, with members working at various partner locations.
Jessica's mother reports a huge difference in her daughter since starting the role, highlighting improved community integration and independence.
Jessica has already engaged positively with company culture by participating in fundraisers for Heart Month and World Epilepsy Day.
Risk Factors
The article focuses entirely on a positive human interest story regarding employment success at Edwards Lifesciences, identifying no specific negative aspects, risks, or downturn metrics to extract.
Viatris chief financial officer Theodora Mistras will leave her current role to join Edwards Lifesciences as CFO starting at the end of May. Mistras, who has held the position since 2024, is scheduled to remain with Viatris until May 22 to ensure a smooth transition. Her compensation package at Edwards Lifesciences includes a base salary of $925,000, a sign-on bonus of approximately $2 million paid immediately upon start, plus additional stock and equity awards. She will be succeeding Scott Ullem, who previously announced in October his intention to transition from the role at Edwards Lifesciences.
Viatris has appointed Paul Campbell as interim CFO effective May 8 while the company searches for a permanent replacement. Campbell, currently serving as Chief Accounting Officer and Corporate Controller, has been with Viatris's legacy company Mylan since 2002 and previously worked at Deloitte & Touche. The leadership change represents significant movement in the healthcare sector as executives shift between major pharmaceutical and medical device firms.
👩💼 Theodora Mistras moves from Viatris CFO to Edwards Lifesciences next month.
💰 She earns a $925k salary and $2 million sign-on bonus at Edwards.
🏛️ Paul Campbell becomes interim CFO at Viatris starting May 8.
👩💼 Theodora Mistras is departing her role as CFO at Viatris to join Edwards Lifesciences in the same position.
📅 She will remain with Viatris until May 22, with her new role starting at the end of May.
🏛️ Mistras serves as Viatris' CFO since 2024 after previously working in healthcare investment banking at Citigroup Global Markets and Goldman Sachs.
⚡ At Edwards Lifesciences, she will succeed Scott Ullem, who is transitioning out of the CFO role after October planning.
💰 Edwards Lifesciences has agreed to a base salary of $925,000 plus an approximately $2 million sign-on bonus for Mistras.
👨💼 Viatris has named Paul Campbell as interim CFO effective May 8 while searching for a permanent successor.
🧾 Campbell was promoted from Chief Accounting Officer and Corporate Controller roles at the company.
🏢 Campbell joined Viatris' legacy company, Mylan, in 2002 after earlier working at Deloitte & Touche.
Bullish Signals
Viatris secures proven CFO Theodora Mistras effective end of May.
Paul Campbell leads as Interim CAO starting May 8.
Campbell brings decades of experience from legacy Mylan and Deloitte.
Risk Factors
Viatris faces instability after CFO Theodora Mistras departs for rival Edwards Lifesciences.
CFO tenure is short, signaling potential internal dissatisfaction or strategic drift.
Company scrambles to find a permanent successor following interim appointee in May.
Immediate leadership vacuum exists while searching for a permanent financial chief.
Uncertainty over financial continuity lingers until May 22 transition completion.
Bullish Signals
Viatris has secured a proven executive, Theodora Mistras, to take over as permanent CFO once her interim tenure concludes at the end of May.
Interim Chief Accounting Officer Paul Campbell, who joined legacy company Mylan in 2002, will lead Viatris starting May 8 while a permanent successor is sought.
Campbell brings extensive industry experience with early career stints at Deloitte & Touche and having worked within the company since its origins.
Risk Factors
Viatris is facing executive instability with the departure of its CFO, Theodora Mistras, who leaves to join competitor Edwards Lifesciences.
Mistras has been CFO since 2024, indicating a relatively short tenure before departing for a rival firm, which could signal internal dissatisfaction or strategic drift.
Viatris is left scrambling to find a permanent successor after only appointing Paul Campbell as interim Chief Accounting Officer and Corporate Controller effective May 8.
Paul Campbell's new role was filled immediately on an interim basis while the company searches for a permanent CFO, highlighting immediate leadership vacuum risks.
The departure of Mistras just weeks before her transition to Edwards Lifescences creates uncertainty over financial continuity at Viatris until May 22.
Edwards Lifesciences has appointed Doretta Mistras as its new Chief Financial Officer, effective at the end of May 2026. She succeeds Scott Ullem, who is stepping down from the role after serving in the position since 2014. Ullem will transition into a strategic advisory role for the Irvine-based heart valve manufacturer following his tenure of over a decade. Prior to joining Edwards Lifesciences, Mistras held the CFO position at pharmaceutical giant Viatris since March 2024, where she led the global finance organization and managed financial planning, reporting, and operational finance. Her previous experience includes serving as a managing director in healthcare investment banking at Citigroup Global Markets and holding senior leadership roles in similar fields at Goldman Sachs. Edwards CEO Bernard Zovighian praised Mistras' decades of experience in corporate finance, strategy, and investor relations, noting that her background will be instrumental in executing the company's differentiated strategy. The announcement highlights the company's commitment to investing in innovation while delivering durable financial results for shareholders, patients, customers, and the broader healthcare ecosystem. Both leaders expressed appreciation for the continuity and discipline defined by Edwards' leadership approach during this transition period.
🗓️ Doretta Mistras joins Edwards as CFO effective May 2026.
🔄 Scott Ullem steps down after 12 years to become a strategic advisor.
💼 Mistras brings decades of healthcare finance experience from Viatris and Goldman Sachs.
🗓️ Doretta Mistras has been appointed as the new Chief Financial Officer for Edwards Lifesciences, with her appointment taking effect at the end of May 2026.
🔄 She succeeds Scott Ullem, who is stepping down from his role after serving as CFO for over a decade since joining in 2014.
👋 Scott Ullem announced his departure in October 2025 and will continue to serve Edwards as a strategic advisor during the transition.
💼 Prior to joining Edwards, Mistras held the position of CFO at pharmaceutical company Viatris since March 2024.
💰 During her tenure at Viatris, she led the global finance organization and oversaw financial planning, reporting, and operational finance.
🏦 Before leading finance at a pharma firm, Mistras served as a managing director in healthcare investment banking at Citigroup Global Markets.
⚖️ Her early career included holding senior leadership roles in healthcare investment banking at Goldman Sachs.
🏥 Edwards highlights Mistras' decades of experience in healthcare leadership across corporate finance, strategy, and investor relations.
🤝 CEO Bernard Zovighian expressed pleasure at welcoming Mistras to the company to execute its differentiated strategy.
🚀 The new CFO's experience is expected to help Edwards invest in innovation while delivering durable financial results and long-term value.
🙏 Edwards publicly thanked Scott Ullem for his outstanding leadership, partnership, and impact on strengthening the company strategically and financially.
🌉 The transition is designed to reflect discipline and continuity, a core aspect of Edwards' approach to leadership over time.
Bullish Signals
Doretta Mistras brings decades of healthcare leadership experience.
She previously led global finance at Viatris since March 2024.
Her background includes senior roles at Goldman Sachs and Citigroup.
CEO Bernard Zovighian notes her experience aids Edwards' strategy.
Company aims to invest in innovation for long-term value.
Risk Factors
Departing CFO Scott Ullem joins 2014 creates transition execution risks.
New CFO Doretta Mistras starts May 2026 after Oct 2025 announcement.
CEO Zovighian implies current performance needs new leadership to stabilize.
Bullish Signals
Doretta Mistras brings decades of healthcare leadership experience across corporate finance, strategy, and investor relations to the role.
She previously led global finance, planning, reporting, and operational finance at Viatris since March 2024, demonstrating significant financial management capability.
Her background includes senior leadership roles at Goldman Sachs and Citigroup Global Markets in healthcare investment banking.
CEO Bernard Zovighian stated that her broad experience will be instrumental as Edwards executes its differentiated strategy to deliver durable financial results.
The company aims to use this leadership continuity to invest in innovation and deliver long-term value to shareholders and the broader healthcare ecosystem.
Scott Ullem, who served as CFO since 2014 for over a decade, will continue as a strategic advisor to ensure disciplined transition and continuity.
Risk Factors
CFO Scott Ullem is departing after more than a decade in the role, joining in 2014, which could introduce execution risks during the transition period.
The new CFO, Doretta Mistras, succeeds Ullem at the end of May 2026, following his announcement to depart in October 2025, creating a significant leadership change with potential operational instability.
CEO Bernard Zovighian's statement highlights the need to 'execute our differentiated strategy' and deliver results, suggesting current financial performance may require new leadership support to stabilize.
Over the past twelve months, Edwards Lifesciences Corporation (NYSE: EW) experienced significant insider selling activity with zero recorded purchases. The most prominent transaction involved Corporate Vice President of Strategy & Corporate Development, Donald Bobo, who sold US$2.0 million worth of shares at an average price of US$83.84 per share, a transaction that represented 13% of his total stake in the company. Because this sale occurred below the recent market price of approximately US$83.98, it suggests that the insider may have believed the lower price to be fair value, potentially indicating concern over the stock's higher current valuation.
Insider ownership remains substantial but low relative to the company's total size, with insiders collectively owning 0.2% of the outstanding shares, currently valued at around US$105 million based on recent pricing. Although this level of insider holding suggests alignment with shareholder interests, the complete absence of buying activity over the last year combined with the substantial volume of selling has raised cautionary flags for analysts monitoring these transactions.
The analysis highlights that while insider sales do not always signal a definitive negative trend, the combination of no buys in three months and significant sells within the same period makes it difficult to argue that current insiders view the shares as a bargain. Furthermore, this specific analysis identified three financial warning signs associated with the company, suggesting investors should proceed with caution and conduct further research into the risks facing Edwards Lifesciences before making investment decisions.
📉 Insiders sold significant shares but made no purchases over the last year.
💰 The largest single sale was $2.0m by Corporate Vice President Donald Bobo.
⚠️ Lack of insider buying suggests current valuations may not be attractive.
📊 Insider ownership is low at 0.2% of a company valued around $105m.
📉 Over the past twelve months, Edwards Lifesciences (EW) insiders have sold significant shares but made no purchases whatsoever.
💰 The largest single insider sale was $2.0m by Corporate Vice President Donald Bobo, who sold at $83.84 per share below the current price.
📊 Insiders currently own approximately 0.2% of the company, which is valued at around $105m based on recent share prices.
⚠️ The absence of any insider buying over the last year suggests insiders may not view the shares as a bargain compared to recent valuations.
📉 In the most recent quarter, substantial selling occurred with no recorded purchases by any insider.
💡 While significant insider ownership generally indicates alignment with shareholder interests, the lack of new investment is viewed skeptically.
⚠️ Analysis of these transactions combined with three identified warning signs suggests caution for potential investors.
📈 This article is a general commentary based on historical data and does not constitute specific financial advice to buy or sell EW stock.
Bullish Signals
Edwards Lifesciences insiders hold shares valued at roughly US$105m.
Significant insider ownership suggests management acts in all shareholders' interests.
Risk Factors
Edwards insiders have made zero share purchases over the last twelve months.
CVP Donald Bobo sold US$2.0m below market at US$83.98 per share.
Substantial insider selling occurred this quarter with no matching purchases.
Three warning signs identified for Edwards Lifesciences indicate potential risks.
Insider ownership is low at 0.2% despite a US$105m stake.
Bullish Signals
Edwards Lifesciences insiders own a significant number of shares, currently worth about US$105m based on the recent share price.
This kind of significant ownership by insiders generally increases the chance that the company is run in the interest of all shareholders.
Risk Factors
Edwards Lifesciences insiders have not purchased any shares over the last twelve months, raising concerns about insider sentiment.
The largest single insider sale involved Corporate Vice President Donald Bobo selling US$2.0m worth of shares below the current market price of US$83.98, suggesting he viewed a lower valuation as fair.
During the last quarter, substantial insider selling occurred with no accompanying purchases, making it difficult to argue that insiders view the current share price as a bargain.
The analysis identified three specific warning signs for Edwards Lifesciences which may indicate underlying financial or operational risks.
Insider ownership remains relatively low at only 0.2% of the company, despite their total stake being worth approximately US$105m.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)